You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArsenic trioxide
Accession NumberDB01169  (APRD00171)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionArsenic trioxide is a chemotheraputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature of arsenic, this drug carries significant health risks. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Structure
Thumb
Synonyms
Acide Arsenieux
Anhydride Arsenieux
Arseneous anhydride
Arseneous oxide
Arseni Trioxydum
Arsenic Blanc
Arsenic oxide
Arsenic Oxidearsenous Trioxide
Arsenic sesquioxide
Arsenic(III) oxide
Arsenicum album
Arsenigen Saure
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Trioxide
Arsenolite
Arsentrioxide
Diarsenic trioxide
Oxyde Arsenieux
Tetraarsenic hexaoxide
White arsenic
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trisenoxinjection, solution1 mg/mLintravenousCephalon, Incorporated2000-10-15Not applicableUs
Trisenoxsolution1 mgintravenousLundbeck Canada Inc2013-09-09Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS7V92P67HO
CAS number1327-53-3
WeightAverage: 197.84
Monoisotopic: 197.827934
Chemical FormulaAs2O3
InChI KeyMOQADKPFYVWPSE-UHFFFAOYSA-N
InChI
InChI=1S/As2O3/c3-1-2(4)5
IUPAC Name
(arsoarsoroso)arsane
SMILES
O=[As][As](=O)=O
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as metalloid oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a metalloid.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassMetalloid organides
Sub ClassMetalloid oxides
Direct ParentMetalloid oxides
Alternative Parents
Substituents
  • Metalloid oxide
  • Inorganic oxide
  • Inorganic metalloid salt
  • Inorganic arsenic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
PharmacodynamicsArsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.
Mechanism of actionThe mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding75% bound
Metabolism

The metabolism of arsenic trioxide involves reduction of pentavalent arsenic to trivalent arsenic by arsenate reductase and methylation of trivalent arsenic to monomethylarsonic acid and monomethylarsonic acid to dimethylarsinic acid by methyltransferases. The main site of methylation reactions appears to be the liver. Arsenic is stored mainly in liver, kidney, heart, lung, hair and nails.

Route of eliminationTrivalent arsenic is mostly methylated in humans and excreted in urine.
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include convulsions, muscle weakness and confusion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9839
Blood Brain Barrier+0.9549
Caco-2 permeable-0.526
P-glycoprotein substrateNon-substrate0.8227
P-glycoprotein inhibitor INon-inhibitor0.9138
P-glycoprotein inhibitor IINon-inhibitor0.9925
Renal organic cation transporterNon-inhibitor0.9297
CYP450 2C9 substrateNon-substrate0.9036
CYP450 2D6 substrateNon-substrate0.829
CYP450 3A4 substrateNon-substrate0.7462
CYP450 1A2 substrateNon-inhibitor0.7393
CYP450 2C9 inhibitorNon-inhibitor0.8625
CYP450 2D6 inhibitorNon-inhibitor0.9133
CYP450 2C19 inhibitorNon-inhibitor0.7968
CYP450 3A4 inhibitorNon-inhibitor0.9567
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9743
Ames testNon AMES toxic0.5978
CarcinogenicityNon-carcinogens0.5984
BiodegradationReady biodegradable0.8156
Rat acute toxicity2.5942 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8253
hERG inhibition (predictor II)Non-inhibitor0.9812
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous1 mg/mL
Solutionintravenous1 mg
Prices
Unit descriptionCostUnit
Trisenox 10 mg/10 ml ampule43.58USD ml
Arsenic trioxide powder2.59USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6723351 No1998-11-102018-11-10Us
US6855339 No1998-11-102018-11-10Us
US6861076 No1998-11-102018-11-10Us
US6884439 No1998-11-102018-11-10Us
US6982096 No1998-11-102018-11-10Us
US8273379 No1998-11-102018-11-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility1.7E+004 mg/L (at 16 °C)SHIU,WY ET AL. (1990)
Predicted Properties
PropertyValueSource
logP0.45ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area51.21 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity4.33 m3·mol-1ChemAxon
Polarizability6.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917 ]
External Links
ATC CodesL01XX27
AHFS Codes
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (46.3 KB)
MSDSDownload (78.3 KB)
Interactions
Drug Interactions
Drug
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Arsenic trioxide.
AcetaminophenThe serum concentration of Arsenic trioxide can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Arsenic trioxide.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.
AfatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Arsenic trioxide.
AlbendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Arsenic trioxide can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Arsenic trioxide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.
AmantadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Arsenic trioxide can be increased when it is combined with Aminohippuric acid.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Arsenic trioxide.
AmitriptylineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Arsenic trioxide.
AmprenavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Arsenic trioxide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Arsenic trioxide.
ArformoterolArformoterol may increase the QTc-prolonging activities of Arsenic trioxide.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherArsenic trioxide may increase the QTc-prolonging activities of Artemether.
AsenapineArsenic trioxide may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Arsenic trioxide can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Arsenic trioxide can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Arsenic trioxide.
AtorvastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Arsenic trioxide can be increased when it is combined with Azelastine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Arsenic trioxide.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Arsenic trioxide.
BenzocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Arsenic trioxide can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Arsenic trioxide.
BiperidenThe serum concentration of Arsenic trioxide can be increased when it is combined with Biperiden.
BortezomibBortezomib may increase the QTc-prolonging activities of Arsenic trioxide.
BosutinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Arsenic trioxide.
BuprenorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Buprenorphine.
BuserelinBuserelin may increase the QTc-prolonging activities of Arsenic trioxide.
BuspironeThe serum concentration of Arsenic trioxide can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Arsenic trioxide can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Arsenic trioxide can be increased when it is combined with Caffeine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.
CanagliflozinThe serum concentration of Arsenic trioxide can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Arsenic trioxide can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Arsenic trioxide can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Arsenic trioxide.
CeritinibCeritinib may increase the QTc-prolonging activities of Arsenic trioxide.
ChloroquineChloroquine may increase the QTc-prolonging activities of Arsenic trioxide.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Arsenic trioxide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Arsenic trioxide.
ChlorpropamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Arsenic trioxide can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Arsenic trioxide.
CilazaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cimetidine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
CisaprideCisapride may increase the QTc-prolonging activities of Arsenic trioxide.
CitalopramCitalopram may increase the QTc-prolonging activities of Arsenic trioxide.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Arsenic trioxide.
ClofazimineThe serum concentration of Arsenic trioxide can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Arsenic trioxide can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Arsenic trioxide can be decreased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clozapine.
ClozapineClozapine may increase the QTc-prolonging activities of Arsenic trioxide.
CobicistatThe serum concentration of Arsenic trioxide can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Arsenic trioxide can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Arsenic trioxide can be increased when it is combined with Colforsin.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Arsenic trioxide.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Arsenic trioxide.
CyclosporineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Cyclosporine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Arsenic trioxide.
DaclatasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Dactinomycin.
DasatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Daunorubicin.
DegarelixDegarelix may increase the QTc-prolonging activities of Arsenic trioxide.
DesfluraneDesflurane may increase the QTc-prolonging activities of Arsenic trioxide.
DesipramineThe serum concentration of Arsenic trioxide can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.
DesloratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Arsenic trioxide can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Arsenic trioxide can be increased when it is combined with Diclofenac.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Arsenic trioxide.
DigoxinDigoxin may decrease the cardiotoxic activities of Arsenic trioxide.
DihydroergotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Arsenic trioxide can be increased when it is combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Arsenic trioxide.
DipyridamoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Dipyridamole.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Arsenic trioxide.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.
DofetilideDofetilide may increase the QTc-prolonging activities of Arsenic trioxide.
DolasetronDolasetron may increase the QTc-prolonging activities of Arsenic trioxide.
DomperidoneArsenic trioxide may increase the QTc-prolonging activities of Domperidone.
DoxazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Arsenic trioxide can be increased when it is combined with Dronabinol.
DronedaroneArsenic trioxide may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Arsenic trioxide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Arsenic trioxide.
ElbasvirThe serum concentration of Arsenic trioxide can be increased when it is combined with Elbasvir.
EliglustatArsenic trioxide may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.
EnalaprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Arsenic trioxide.
ErythromycinErythromycin may increase the QTc-prolonging activities of Arsenic trioxide.
EscitalopramArsenic trioxide may increase the QTc-prolonging activities of Escitalopram.
EstramustineThe serum concentration of Arsenic trioxide can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Arsenic trioxide can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Arsenic trioxide can be increased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Arsenic trioxide.
EzogabineEzogabine may increase the QTc-prolonging activities of Arsenic trioxide.
FamotidineFamotidine may increase the QTc-prolonging activities of Arsenic trioxide.
FelbamateFelbamate may increase the QTc-prolonging activities of Arsenic trioxide.
FelodipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Arsenic trioxide can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Arsenic trioxide can be increased when it is combined with Fidaxomicin.
FingolimodFingolimod may increase the QTc-prolonging activities of Arsenic trioxide.
FlecainideFlecainide may increase the QTc-prolonging activities of Arsenic trioxide.
FluconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluconazole.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Arsenic trioxide.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Arsenic trioxide.
FluphenazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Arsenic trioxide.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Arsenic trioxide.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Arsenic trioxide.
GalantamineGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.
GefitinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Gefitinib.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
GenisteinThe serum concentration of Arsenic trioxide can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Arsenic trioxide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Arsenic trioxide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Arsenic trioxide.
GlyburideThe serum concentration of Arsenic trioxide can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Arsenic trioxide can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Arsenic trioxide.
Gramicidin DThe serum concentration of Arsenic trioxide can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Arsenic trioxide.
GrepafloxacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Grepafloxacin.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Arsenic trioxide.
HistrelinHistrelin may increase the QTc-prolonging activities of Arsenic trioxide.
HydrocortisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Hydrocortisone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Arsenic trioxide.
IbandronateIbandronate may increase the QTc-prolonging activities of Arsenic trioxide.
IbutilideIbutilide may increase the QTc-prolonging activities of Arsenic trioxide.
IdelalisibThe serum concentration of Arsenic trioxide can be increased when it is combined with Idelalisib.
IloperidoneArsenic trioxide may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Arsenic trioxide can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.
IndapamideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.
IndinavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Arsenic trioxide can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Arsenic trioxide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Arsenic trioxide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Arsenic trioxide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Arsenic trioxide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Arsenic trioxide.
IsavuconazoniumThe serum concentration of Arsenic trioxide can be increased when it is combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Arsenic trioxide.
IsradipineIsradipine may increase the QTc-prolonging activities of Arsenic trioxide.
ItraconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Arsenic trioxide.
IvacaftorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Arsenic trioxide can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Lapatinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Arsenic trioxide.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Arsenic trioxide.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
LevothyroxineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Arsenic trioxide can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.
LiothyronineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Arsenic trioxide can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Arsenic trioxide.
LisinoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Lisinopril.
LithiumLithium may increase the QTc-prolonging activities of Arsenic trioxide.
LomitapideThe serum concentration of Arsenic trioxide can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Arsenic trioxide can be increased when it is combined with Loperamide.
LopinavirArsenic trioxide may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Lumacaftor.
LumefantrineArsenic trioxide may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineThe serum concentration of Arsenic trioxide can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Arsenic trioxide can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Arsenic trioxide can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Arsenic trioxide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.
MethadoneMethadone may increase the QTc-prolonging activities of Arsenic trioxide.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Arsenic trioxide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Arsenic trioxide.
MetoprololThe serum concentration of Arsenic trioxide can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Arsenic trioxide.
MibefradilThe serum concentration of Arsenic trioxide can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Arsenic trioxide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Arsenic trioxide.
MirabegronMirabegron may increase the QTc-prolonging activities of Arsenic trioxide.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Arsenic trioxide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Arsenic trioxide.
MitomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Mitoxantrone.
MoexiprilMoexipril may increase the QTc-prolonging activities of Arsenic trioxide.
MorphineThe serum concentration of Arsenic trioxide can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
NaltrexoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Arsenic trioxide can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Arsenic trioxide.
NefazodoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Arsenic trioxide can be increased when it is combined with Neostigmine.
NicardipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nifedipine.
NilotinibArsenic trioxide may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Arsenic trioxide.
NisoldipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Arsenic trioxide.
OctreotideOctreotide may increase the QTc-prolonging activities of Arsenic trioxide.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Arsenic trioxide.
OmeprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Arsenic trioxide.
OuabainOuabain may decrease the cardiotoxic activities of Arsenic trioxide.
OxytocinOxytocin may increase the QTc-prolonging activities of Arsenic trioxide.
P-NitrophenolThe serum concentration of Arsenic trioxide can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Arsenic trioxide can be increased when it is combined with Paclitaxel.
PaliperidoneArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Palmitic Acid.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Arsenic trioxide.
PantoprazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Arsenic trioxide can be increased when it is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Arsenic trioxide.
PazopanibPazopanib may increase the QTc-prolonging activities of Arsenic trioxide.
PentamidinePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.
PerflutrenPerflutren may increase the QTc-prolonging activities of Arsenic trioxide.
PerindoprilThe serum concentration of Arsenic trioxide can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Arsenic trioxide.
PhenobarbitalThe serum concentration of Arsenic trioxide can be decreased when it is combined with Phenobarbital.
PimozidePimozide may increase the QTc-prolonging activities of Arsenic trioxide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Arsenic trioxide.
Platelet Activating FactorThe serum concentration of Arsenic trioxide can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Arsenic trioxide can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Arsenic trioxide.
PravastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Arsenic trioxide.
ProbenecidThe serum concentration of Arsenic trioxide can be increased when it is combined with Probenecid.
ProcainamideProcainamide may increase the QTc-prolonging activities of Arsenic trioxide.
ProgesteroneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Progesterone.
PromazinePromazine may increase the QTc-prolonging activities of Arsenic trioxide.
PromethazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Promethazine.
PropafenonePropafenone may increase the QTc-prolonging activities of Arsenic trioxide.
PropofolPropofol may increase the QTc-prolonging activities of Arsenic trioxide.
PropranololThe serum concentration of Arsenic trioxide can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Arsenic trioxide can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Arsenic trioxide can be increased when it is combined with Quercetin.
QuetiapineArsenic trioxide may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinacrine.
QuinidineQuinidine may increase the QTc-prolonging activities of Arsenic trioxide.
QuinineQuinine may increase the QTc-prolonging activities of Arsenic trioxide.
RanitidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Arsenic trioxide can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Arsenic trioxide can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Arsenic trioxide.
ReserpineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Reserpine.
RifampicinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Arsenic trioxide can be increased when it is combined with Rilpivirine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Arsenic trioxide.
RitonavirThe serum concentration of Arsenic trioxide can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Arsenic trioxide can be increased when it is combined with Rolapitant.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Arsenic trioxide.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Arsenic trioxide.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Arsenic trioxide.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Arsenic trioxide.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Arsenic trioxide.
ScopolamineThe serum concentration of Arsenic trioxide can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Arsenic trioxide can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Arsenic trioxide can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Arsenic trioxide.
SimeprevirThe serum concentration of Arsenic trioxide can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Arsenic trioxide can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Arsenic trioxide.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Arsenic trioxide.
SorafenibThe serum concentration of Arsenic trioxide can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Arsenic trioxide.
SpironolactoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Arsenic trioxide can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Arsenic trioxide can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Arsenic trioxide can be decreased when it is combined with Streptozocin.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Arsenic trioxide.
SulfinpyrazoneThe serum concentration of Arsenic trioxide can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Arsenic trioxide.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Arsenic trioxide.
SumatriptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Arsenic trioxide can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Arsenic trioxide can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Arsenic trioxide can be increased when it is combined with Taurocholic Acid.
TelavancinTelavancin may increase the QTc-prolonging activities of Arsenic trioxide.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Arsenic trioxide.
TelmisartanThe serum concentration of Arsenic trioxide can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Arsenic trioxide can be increased when it is combined with Terazosin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Arsenic trioxide.
TerfenadineThe serum concentration of Arsenic trioxide can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Arsenic trioxide can be increased when it is combined with Testosterone.
TetrabenazineArsenic trioxide may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Arsenic trioxide.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.
TicagrelorThe serum concentration of Arsenic trioxide can be increased when it is combined with Ticagrelor.
TizanidineTizanidine may increase the QTc-prolonging activities of Arsenic trioxide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.
TolterodineTolterodine may increase the QTc-prolonging activities of Arsenic trioxide.
TolvaptanThe serum concentration of Arsenic trioxide can be increased when it is combined with Tolvaptan.
ToremifeneToremifene may increase the QTc-prolonging activities of Arsenic trioxide.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Arsenic trioxide.
TrazodoneThe serum concentration of Arsenic trioxide can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Arsenic trioxide.
TrifluoperazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Arsenic trioxide can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Arsenic trioxide can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Arsenic trioxide can be increased when it is combined with Trimipramine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Arsenic trioxide.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Arsenic trioxide.
TroleandomycinThe serum concentration of Arsenic trioxide can be increased when it is combined with Troleandomycin.
VandetanibArsenic trioxide may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Arsenic trioxide.
VemurafenibArsenic trioxide may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Arsenic trioxide can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Arsenic trioxide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Arsenic trioxide.
VinblastineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Arsenic trioxide can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Arsenic trioxide can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Arsenic trioxide.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Arsenic trioxide.
VorinostatVorinostat may increase the QTc-prolonging activities of Arsenic trioxide.
ZimelidineThe serum concentration of Arsenic trioxide can be increased when it is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Arsenic trioxide.
ZuclopenthixolArsenic trioxide may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These mo...
Gene Name:
IKBKB
Uniprot ID:
O14920
Molecular Weight:
86563.245 Da
References
  1. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390 ]
  2. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740 ]
  3. Ouyang W, Zhang D, Ma Q, Li J, Huang C: Cyclooxygenase-2 induction by arsenite through the IKKbeta/NFkappaB pathway exerts an antiapoptotic effect in mouse epidermal Cl41 cells. Environ Health Perspect. 2007 Apr;115(4):513-8. Epub 2006 Dec 14. [PubMed:17450217 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thioredoxin-disulfide reductase activity
Specific Function:
Isoform 1 may possess glutaredoxin activity as well as thioredoxin reductase activity and induces actin and tubulin polymerization, leading to formation of cell membrane protrusions. Isoform 4 enhances the transcriptional activity of estrogen receptors alpha and beta while isoform 5 enhances the transcriptional activity of the beta receptor only. Isoform 5 also mediates cell death induced by a ...
Gene Name:
TXNRD1
Uniprot ID:
Q16881
Molecular Weight:
70905.58 Da
References
  1. Lu J, Chew EH, Holmgren A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. Epub 2007 Jul 18. [PubMed:17640917 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function:
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.
Gene Name:
JUN
Uniprot ID:
P05412
Molecular Weight:
35675.32 Da
References
  1. Muscarella DE, Bloom SE: Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol Sci. 2002 Jul;68(1):82-92. [PubMed:12075113 ]
  2. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127 ]
  3. Drobna Z, Jaspers I, Thomas DJ, Styblo M: Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J. 2003 Jan;17(1):67-9. Epub 2002 Nov 15. [PubMed:12475910 ]
  4. Li J, Gorospe M, Barnes J, Liu Y: Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts. J Biol Chem. 2003 Apr 11;278(15):13183-91. Epub 2003 Jan 23. [PubMed:12547826 ]
  5. Kietzmann T, Samoylenko A, Immenschuh S: Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes. J Biol Chem. 2003 May 16;278(20):17927-36. Epub 2003 Mar 11. [PubMed:12637567 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcription factor binding
Specific Function:
Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progres...
Gene Name:
CCND1
Uniprot ID:
P24385
Molecular Weight:
33728.74 Da
References
  1. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, Hyuck Im Y, Lee MH, Ki Kang W, Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun. 2003 Jan 3;300(1):230-5. [PubMed:12480548 ]
  2. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, Huang C: Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res. 2005 Oct 15;65(20):9287-93. [PubMed:16230390 ]
  3. Ouyang W, Li J, Ma Q, Huang C: Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis. 2006 Apr;27(4):864-73. Epub 2005 Dec 29. [PubMed:16387740 ]
  4. Hwang BJ, Utti C, Steinberg M: Induction of cyclin D1 by submicromolar concentrations of arsenite in human epidermal keratinocytes. Toxicol Appl Pharmacol. 2006 Dec 1;217(2):161-7. Epub 2006 Aug 11. [PubMed:17005224 ]
  5. Ouyang W, Li J, Zhang D, Jiang BH, Huang DC: PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J Cell Biochem. 2007 Jul 1;101(4):969-78. [PubMed:17370311 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Phosphatase binding
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell...
Gene Name:
MAPK3
Uniprot ID:
P27361
Molecular Weight:
43135.16 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888 ]
  2. Jung DK, Bae GU, Kim YK, Han SH, Choi WS, Kang H, Seo DW, Lee HY, Cho EJ, Lee HW, Han JW: Hydrogen peroxide mediates arsenite activation of p70(s6k) and extracellular signal-regulated kinase. Exp Cell Res. 2003 Oct 15;290(1):144-54. [PubMed:14516795 ]
  3. Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H, Ando M: Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol. 2003 Dec;149(6):1116-27. [PubMed:14674888 ]
  4. Felix K, Manna SK, Wise K, Barr J, Ramesh GT: Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol. 2005;19(2):67-77. [PubMed:15849723 ]
  5. Mousa SA, O'Connor L, Rossman TG, Block E: Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis. 2007 May;28(5):962-7. Epub 2006 Dec 8. [PubMed:17158527 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Rna polymerase ii carboxy-terminal domain kinase activity
Specific Function:
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell...
Gene Name:
MAPK1
Uniprot ID:
P28482
Molecular Weight:
41389.265 Da
References
  1. Dong Z: The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9. [PubMed:12426127 ]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Protein serine/threonine/tyrosine kinase activity
Specific Function:
AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of ...
Gene Name:
AKT1
Uniprot ID:
P31749
Molecular Weight:
55686.035 Da
References
  1. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM: Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem. 2002 Dec;83(6):1338-48. [PubMed:12472888 ]
  2. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z: Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J Biol Chem. 2003 Mar 21;278(12):10588-93. Epub 2003 Jan 14. [PubMed:12529330 ]
  3. Ivanov VN, Hei TK: Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. 2005 Jan 20;24(4):616-26. [PubMed:15580309 ]
  4. Wang ZX, Jiang CS, Liu L, Wang XH, Jin HJ, Wu Q, Chen Q: The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res. 2005 May;15(5):379-86. [PubMed:15916724 ]
  5. Tsou TC, Tsai FY, Hsieh YW, Li LA, Yeh SC, Chang LW: Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol Appl Pharmacol. 2005 Nov 1;208(3):277-84. [PubMed:16239170 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JI, Schrenk D: Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46. [PubMed:11836020 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Hu XM, Hirano T, Oka K: Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. Epub 2002 Nov 20. [PubMed:12647012 ]
  2. Wei HL, Yao XJ, Li YN, Wang P, Zhao HS, Bai DC, Peng X, Ma LF: [Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31. [PubMed:12679007 ]
  3. Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X, Ma L: Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl). 2003 Nov;116(11):1644-8. [PubMed:14642128 ]
  4. Kimura A, Ishida Y, Wada T, Yokoyama H, Mukaida N, Kondo T: MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. Toxicol Appl Pharmacol. 2005 Feb 15;203(1):53-61. [PubMed:15694464 ]
  5. Cronin CJ, Mendel JE, Mukhtar S, Kim YM, Stirbl RC, Bruck J, Sternberg PW: An automated system for measuring parameters of nematode sinusoidal movement. BMC Genet. 2005 Feb 7;6:5. [PubMed:15698479 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26